

Procter & Gamble Hygiene and Health Care Limited CIN: L24239MH1964PLC012971 Registered Office: P&G Plaza Cardinal Gracias Road, Chakala Andheri (E), Mumbai 400 099 Tel: (91-22) 6958 6000 Fax: (91-22) 6958 7337 Website: in.pg.com

	STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th JUNE 2024 (₹ in Lakh:						
		(1)	(2)	(3)	(4)	(5)	
			Preceding	Corresponding		Previous	
	Particulars	Three Months	Three Months	Three Months	Year	Year	
		Ended	Ended	Ended	Ended	Ended	
		30th June 2024	31st March 2024	30th June 2023	30th June 2024	30th June 2023	
		(Audited) Refer Note 12	(Unaudited)	(Audited) Refer Note 12	(Audited)	(Audited)	
1	Income						
	Sale of products	92 743	99 815	84 874	4 19 157	3 90 521	
	Other operating revenues	432	402	379	1 413	1 269	
2	Revenue from operations	93 175	1 00 217	85 253	4 20 570	3 91 790	
3	Other income	731	1 359	1 010	5 225	4 058	
	Total income (2+3)	93 906	1 01 576	86 263	4 25 795	3 95 848	
	` ,						
4	Expenses						
a)	Cost of raw and packing materials consumed	17 685	16 400	19 990	77 194	84 755	
b)	Purchases of stock-in-trade (Traded goods)	23 180	18 086	19 309	85 438	82 401	
c)	Changes in inventories of finished goods, work-in-progress and stock-in- trade	( 2830)	( 710)	( 3 321)	( 1 213)	( 853)	
d)	Employee benefits expense	6 713	6 009	4 807	24 564	20 579	
e)	Finance costs	( 8)	2 242	300	2 678	1 138	
f)	Depreciation and amortization expense	1 340	1 454	1 541	5 650	5 836	
g)	Impairment losses (Refer Note 7)	1 303			1 303		
g)	Advertising & sales promotion expenses	15 371	13 409	5 354	56 797	42 652	
h)	Other expenses	19 924	21 292	17 625	79 464	75 393	
ŕ	Total expenses	82 678	78 182	65 605	3 31 875	3 11 901	
	·						
5	Profit before tax (2+3-4)	11 228	23 394	20 658	93 920	83 947	
6	Tax expense						
a)	Current tax	3 292	6 967	5 448	25 955	23 052	
b)	Deferred tax	( 167)	( 820)	86	( 1586)	( 1 208)	
c)	Prior year tax adjustments	( 3)	1 810		2 049	( 5 711)	
		3 122	7 957	5 534	26 418	16 133	
7	Profit for the period (5-6)	8 106	15 437	15 124	67 502	67 814	
8	Other comprehensive income						
	Items that will not be reclassified to profit or loss:						
	Remeasurement of the defined benefit plans	( 186)	429	( 989)	738	( 999)	
	Income tax effect on above	47	( 108)	248	( 186)	251	
	Total other comprehensive income for the period	( 139)	321	( 741)	552	( 748)	
9	Total comprehensive income for the period (7+8)	7 967	15 758	14 383	68 054	67 066	
10	Paid-up equity share capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 246	3 246	
11	Other Equity				74 240	91 357	
12	Earnings per Share (Face value of ₹ 10 per equity share) (not						
'-	annualised):						
a)	Basic	24.97	47.56	46.59	207.95	208.91	
b)	Diluted	24.97	47.56	46.59	207.95	208.91	
Sec	accompanying notes to the financial results						

## Notes:

Statement of Assets and Liabilities		(₹ in Lakhs)
	As at	As at
Particulars	30 <sup>th</sup> June 2024 (Audited)	30 <sup>th</sup> June 2023 (Audited)
ASSETS	(Flacitor)	(riaditou)
Non-current assets		
Property, plant and equipment	13 916	17 004
Capital work-in-progress	2 775	2 276
Financial assets		
(i) Loans	3 146	2 737
(ii) Other financial assets	955	909
Deferred tax assets (Net)	7 487	6 554
Non-current tax assets (Net)	25 919	24 622
Other non-current assets	11 690	10 060
Total non-current assets	65 888	64 162
Current assets		
Inventories	22 556	21 980
Financial assets		
(i) Trade receivables	24 083	21 628
(ii) Cash and cash equivalents	57 367	96 383
(iii) Bank balances other than (ii) above	1 453	1 416
(iv) Loans	389	369
(v) Other financial assets	8 924	3 277
Other current assets	5 196	4 517
	1 19 968	1 49 570
Non current assets held for sale		
Total current assets	1 19 968	1 49 570
Total Assets	1 85 856	2 13 732
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital	3 246	3 246
Other equity	74 240	91 357
Total Equity	77 486	94 603
Total Equity	77 400	34 003
LIABILITIES		
Non-current liabilities		
Financial liabilities		
(i) Lease liabilities	1	84
Provisions	10 303	10 542
Total non-current liabilities	10 304	10 626
Current liabilities		
Financial liabilities		
(i) Lease liabilities	307	319
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	717	1 946
Total outstanding dues of creditors other than micro enterprises and small	84 448	95 161
enterprises (iii) Other financial liabilities	3 165	2 538
Other current liabilities	4 791	2 538 4 934
Other current liabilities Provisions	1 055	4 934 1 035
Current tax liabilities (net)	3 583	2 570
Total current liabilities		
	98 066	1 08 503
Total Liabilities	1 08 370	1 19 129
Total Equity and Liabilities	1 85 856	2 13 732

2 Statement of Cash Flows

(₹	in	l akhe)

Statement of Cash Flows		(₹ in Lakhs)	
	Year Ended	Year Ended	
Particulars	30 <sup>th</sup> June 2024	30 <sup>th</sup> June 2023	
	(Audited)	(Audited)	
A. Cash Flows from Operating Activities			
Profit before tax	93 920	83 947	
Adjustments for:			
Depreciation and amortization expense	5 650	5 836	
Loss on disposal of property, plant and equipment	554	83	
Finance costs	734	1 138	
Allowance for doubtful receivables (Net of recovery)	99	109	
Interest income	( 4 399)	( 3 508)	
Impairment losses	1 303		
Net foreign exchange (gain)	158	38	
Inventory written off (net of Insurance claims recovered)	1 261	896	
Provisions no longer required written back	( 694)	( 408)	
Expense recognised in respect of equity settled share based payments	850	848	
Operating profit before working capital changes	99 436	88 979	
Working capital adjustments			
(Increase) in trade and other receivables	( 2 554)	( 2511)	
(Increase) / Decrease in financial assets	( 6 156)	( 866)	
(Increase) / Decrease in inventories	( 1 837)	526	
(Increase) in other assets	( 2 309)	( 2 029)	
(Decrease) / Increase in trade and other payables	( 11 549)	20 695	
(Decrease) / Increase in trade and other payables	( 156)	737	
Cash generated from operations	74 875	1 05 531	
Income taxes paid	( 27 822)	( 22 954)	
· · · · · · · · · · · · · · · · · · ·	47 053	82 577	
Net cash generated from operating activities	47 053	02 377	
B. Cook Flavor from Investing Assisting			
B. Cash Flows from Investing Activities	( 70,000)		
Loan given to related parties	( 70 000) 70 000		
Loan repaid by related parties	4 433	3 451	
Interest received			
Payment to acquire property, plant and equipment	( 4 468)	( 4 444)	
Proceeds from sale of property, plant and equipment	141	2	
Changes in earmarked balances			
Net cash generated (used in) investing activities	106	( 991)	
C. Cash Flows from Financing Activities			
Dividend paid	( 86 021)	( 47 068)	
Principal payment of lease liabilities	( 95)	( 107)	
Interest paid on lease liabilities	( 8)	( 12)	
Interest paid other than on lease liabilities	( 51)	( 514)	
Net cash (used in) financing activities	( 86 175)	( 47 701)	
Net (decrease) / increase in cash and cash equivalents	( 39 017)	33 885	
Cash and cash equivalents at the beginning of the year	96 383	62 498	
Effect of exchange differences on translation of foreign currency cash and		7	
cash equivalents		•	
Cash and cash equivalents at the end of the period / year	57 367	96 383	

- 3 The above audited financial results for the quarter and year ended June 30, 2024, have been reviewed and recommended by the Audit Committee, and approved by the Board of Directors of the Company at their respective meetings held on August 28, 2024. These financial results have been subject to an audit by the statutory auditors of the Company, who have expressed an unmodified opinion thereon. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 4 The Financial Results are prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS), as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India.
- The Board of Directors at its meeting held on August 28, 2024 have recommended a payment of final dividend of ₹ 95 per equity share of face value ₹10 each aggregating to ₹ 30 838 lakhs.
- 6 The Company has arrived at an Advanced Pricing Agreement with the concerned tax authorities, determining appropriate transfer pricing methodology for certain identified transactions with the Company's affiliate(s) for the financial years 2010-11 to 2018-19. As a consequence of this agreement, an additional tax liability, amounting to ₹ 1 556 lakh, and interest amounting to ₹ 1 944 lakhs, have been accounted as Prior Period Tax Adjustments and Finance Costs respectively. In view of the above, contingent liabilities have been reduced by ₹ 8 699 lakhs.
- 7 Certain Property, Plant & Equipment of the Company having a written down value of ₹ 2 282 lakhs as at 30 June, 2024, which were licensed to a contract manufacturer whose arrangement was terminated in F.Y. 2022-23, have been tested for impairment and a loss amounting to ₹ 1303 lakhs has been recognized in the financial results for the quarter and year ended June 30, 2024.
- 8 During the preceding year, the Company had reversed tax provisions amounting to ₹5 844 lakhs in respect of past Income Tax Litigations pertaining to certain years, based on a favourable ruling by the Income Tax Appellate Tribunal in a similar case of the Company pertaining to an earlier year.
- 9 The Company has identified Health and Hygiene Products as its single primary reportable segment in accordance with the requirements of Ind AS 108 Operating Segments. Accordingly, no separate segment information has been provided.
- 10 The Statement of Assets and Liabilities as at June 30, 2024, is attached therewith as Note 1.
- 11 The Statement of Cash Flows for the year ended June 30, 2024, has been prepared under the indirect method as set out in Ind AS -7 on the "Statement of Cash Flows" and is attached herewith as Note 2.
- 12 The figures of last quarter ended June 30 are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the respective financial years.

For and on behalf of the Board of Directors of Procter & Gamble Hygiene and Health Care Limited